BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Cancer / Immunology

Dizal Reports ZEGFROVY Achieves Superior Progression Free Survival In Phase 3 WU KONG28 Trial For EGFR Exon20ins NSCLC

Treatment with ZEGFROVY® resulted in statistically significant and clinically meaningful improvement in progression free survival (PFS) over pla...

March 23, 2026 | News

Excalipoint Therapeutics Secures 68.7 Million Dollar Seed Financing To Advance Next Generation T Cell Engager Platforms

Funding to advance proprietary T-cell engager platforms and pipeline of highly differentiated T-cell engager therapies targeting solid tumors and autoi...

March 20, 2026 | News

Innorna Secures FDA Clearance For First In Class mRNA Therapy IN026 In Refractory Gout

IN026 is a potential first-in-class mRNA therapy for refractory gout, marking the emergence of a new category of mRNA medicines enabled by Innorna's propri...

March 19, 2026 | News

Australia Grants CTA For First In Human KMCAR T Cell Therapy Targeting Multiple Myeloma

Clinical Trial Approval (CTA) granted by Australia’s Therapeutic Goods Administration (TGA) for KMCAR™ T-cell, a first-in-human CAR-T cell th...

March 18, 2026 | News

Celltrion Expands US Immunology Portfolio With AVTOZMA Subcutaneous Tocilizumab Biosimilar

AVTOZMA® (tocilizumab-anoh) is among the first wave of tocilizumab biosimilars with both intravenous (IV) and subcutaneous (SC) formulations app...

March 17, 2026 | News

Meiji Seika Pharma Initiates Phase I Trial Of ME3241 PD 1 Agonist Antibody For Autoimmune Diseases

Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) announced that it has in...

March 12, 2026 | News

Vaxcellbio And Reber Genetics Form Strategic Partnership To Expand Companion Animal Immunotherapy Across Asia

Vaxcellbio (CEO Je-Jung Lee, MD, PhD), a leading immuno-oncology company, announced on Wednesday that it has signed a Master Partnership Agreement (MPA) wi...

March 12, 2026 | News

Leads Biolabs Doses First Patient In Phase II Trial Of PD L1 4 1BB Bispecific Antibody For Esophageal Cancer

Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) announced on March 6, 2026 that the first patient has bee...

March 10, 2026 | News

Akeso Reports Durable Long Term Survival Benefit Of Cadonilimab In Advanced Cervical Cancer

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the latest long-term survival analysis data from the China pivotal registrational Phase II ...

March 06, 2026 | Report

Ono Pharmaceutical And Congruence Expand Research Alliance Into Neurology And Immunology

Expanded collaboration continues to leverage Congruence's proprietary computational drug discovery engine, Revenir™ to deliver Development Candi...

March 04, 2026 | News

Pfizer And Astellas Report Strong Phase III EV 304 Results For PADCEV Plus Pembrolizumab In MIBC

In the Phase 3 EV-304 trial, statistically significant improvements in overall survival and pathological complete response were also observed, with ove...

March 02, 2026 | News

Optellum Secures TGA Approval In Australia For AI Powered Virtual Nodule Clinic

Optellum, the leading AI-enabled solution for earlier lung cancer detection, is thrilled to announce that it has received Therapeutic Goods Administration ...

March 02, 2026 | News

WuXi XDC And Earendil Labs Forge Strategic Alliance To Advance Next Generation AI Designed ADCs

WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializin...

March 02, 2026 | News

Astellas And Vir Biotechnology Forge Global Partnership To Advance VIR 5500 In Prostate Cancer

- Astellas and Vir Biotechnology to co-develop and co-commercialize VIR-5500 through a sharing of expenses and revenues - - Astellas to lead commerci...

February 25, 2026 | News

Stay Connected